Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

N. Tandon, S Vincent Rajkumar, B. LaPlant, A. Pettinger, Martha Lacy, Angela Dispenzieri, F. K. Buadi, Morie Gertz, S. R. Hayman, N. Leung, R. S. Go, David M Dingli, Prashant Kapoor, Yi Lin, Y. L. Hwa, A. L. Fonder, M. A. Hobbs, S. R. Zeldenrust, J. A. Lust, Wilson GonsalvesStephen J Russell, Shaji K Kumar

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2.3 years for Cohorts 1 and 2, respectively. Among 1067 patients evaluable in Cohort 1, the median OS and PFS was 10 and 2.8 years for RISS stage I, 6 and 2.7 years for RISS stage II and 2.6 and 1.3 years for RISS stage III (P<0.0001). Among 456 patients evaluable in Cohort 2, the median OS and PFS was 4.3 and 1.1 years for RISS stage I, 2 and 0.5 years for RISS stage II and 0.8 and 0.2 years for RISS stage III (P<0.0001). In conclusions, RISS gives a better differentiation of NDMM as well as RRMM patients into three survival subgroups and should be used to stratify patients in future clinical trials.

Original languageEnglish (US)
Pages (from-to)e528
JournalBlood Cancer Journal
Volume7
Issue number2
DOIs
StatePublished - Feb 17 2017

Fingerprint

Multiple Myeloma
Disease-Free Survival
Survival
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. / Tandon, N.; Rajkumar, S Vincent; LaPlant, B.; Pettinger, A.; Lacy, Martha; Dispenzieri, Angela; Buadi, F. K.; Gertz, Morie; Hayman, S. R.; Leung, N.; Go, R. S.; Dingli, David M; Kapoor, Prashant; Lin, Yi; Hwa, Y. L.; Fonder, A. L.; Hobbs, M. A.; Zeldenrust, S. R.; Lust, J. A.; Gonsalves, Wilson; Russell, Stephen J; Kumar, Shaji K.

In: Blood Cancer Journal, Vol. 7, No. 2, 17.02.2017, p. e528.

Research output: Contribution to journalArticle

@article{b782fefe872146369c920eb2362abcd8,
title = "Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma",
abstract = "We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2.3 years for Cohorts 1 and 2, respectively. Among 1067 patients evaluable in Cohort 1, the median OS and PFS was 10 and 2.8 years for RISS stage I, 6 and 2.7 years for RISS stage II and 2.6 and 1.3 years for RISS stage III (P<0.0001). Among 456 patients evaluable in Cohort 2, the median OS and PFS was 4.3 and 1.1 years for RISS stage I, 2 and 0.5 years for RISS stage II and 0.8 and 0.2 years for RISS stage III (P<0.0001). In conclusions, RISS gives a better differentiation of NDMM as well as RRMM patients into three survival subgroups and should be used to stratify patients in future clinical trials.",
author = "N. Tandon and Rajkumar, {S Vincent} and B. LaPlant and A. Pettinger and Martha Lacy and Angela Dispenzieri and Buadi, {F. K.} and Morie Gertz and Hayman, {S. R.} and N. Leung and Go, {R. S.} and Dingli, {David M} and Prashant Kapoor and Yi Lin and Hwa, {Y. L.} and Fonder, {A. L.} and Hobbs, {M. A.} and Zeldenrust, {S. R.} and Lust, {J. A.} and Wilson Gonsalves and Russell, {Stephen J} and Kumar, {Shaji K}",
year = "2017",
month = "2",
day = "17",
doi = "10.1038/bcj.2017.13",
language = "English (US)",
volume = "7",
pages = "e528",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

AU - Tandon, N.

AU - Rajkumar, S Vincent

AU - LaPlant, B.

AU - Pettinger, A.

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Buadi, F. K.

AU - Gertz, Morie

AU - Hayman, S. R.

AU - Leung, N.

AU - Go, R. S.

AU - Dingli, David M

AU - Kapoor, Prashant

AU - Lin, Yi

AU - Hwa, Y. L.

AU - Fonder, A. L.

AU - Hobbs, M. A.

AU - Zeldenrust, S. R.

AU - Lust, J. A.

AU - Gonsalves, Wilson

AU - Russell, Stephen J

AU - Kumar, Shaji K

PY - 2017/2/17

Y1 - 2017/2/17

N2 - We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2.3 years for Cohorts 1 and 2, respectively. Among 1067 patients evaluable in Cohort 1, the median OS and PFS was 10 and 2.8 years for RISS stage I, 6 and 2.7 years for RISS stage II and 2.6 and 1.3 years for RISS stage III (P<0.0001). Among 456 patients evaluable in Cohort 2, the median OS and PFS was 4.3 and 1.1 years for RISS stage I, 2 and 0.5 years for RISS stage II and 0.8 and 0.2 years for RISS stage III (P<0.0001). In conclusions, RISS gives a better differentiation of NDMM as well as RRMM patients into three survival subgroups and should be used to stratify patients in future clinical trials.

AB - We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2.3 years for Cohorts 1 and 2, respectively. Among 1067 patients evaluable in Cohort 1, the median OS and PFS was 10 and 2.8 years for RISS stage I, 6 and 2.7 years for RISS stage II and 2.6 and 1.3 years for RISS stage III (P<0.0001). Among 456 patients evaluable in Cohort 2, the median OS and PFS was 4.3 and 1.1 years for RISS stage I, 2 and 0.5 years for RISS stage II and 0.8 and 0.2 years for RISS stage III (P<0.0001). In conclusions, RISS gives a better differentiation of NDMM as well as RRMM patients into three survival subgroups and should be used to stratify patients in future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85032793945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032793945&partnerID=8YFLogxK

U2 - 10.1038/bcj.2017.13

DO - 10.1038/bcj.2017.13

M3 - Article

C2 - 28211889

AN - SCOPUS:85032793945

VL - 7

SP - e528

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 2

ER -